Guidelines International Network (GIN)
Powered by EBSCO

Guidelines International Network

1061 - 1070 of 3570 results found

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of Targeted and Biological Therapies: An Infectious Diseases Perspective (Agents Targeting Lymphoid Cells Surface Antigens [I]: CD19, CD20 and CD52)

MeSH Terms
Biological Therapy (E02.095); Infectious Disease Medicine (H02.403.429.480)
Guideline Contact
Chiara Speziale (guidancedocuments@escmid.org)
Publication Scope
treatment
Guideline Publication Status
Published
Languages
English
Authors
ESCMID
Publication Year
2018

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways)

MeSH Terms
Biological Therapy (E02.095); Infectious Disease Medicine (H02.403.429.480)
Guideline Contact
Chiara Speziale (guidancedocuments@escmid.org)
Publication Scope
treatment
Guideline Publication Status
Published
Languages
English
Authors
ESCMID
Publication Year
2018

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of Targeted and Biological Therapies: An Infectious Diseases Perspective (Intracellular Signaling Pathways: Tyrosine Kinase and mTOR Inhibitors)

MeSH Terms
Biological Therapy (E02.095); Protein-Tyrosine Kinases (D08.811.913.696.620.682.725); Receptor Protein-Tyrosine Kinases (D08.811.913.696.620.682.725.400); Receptor Protein-Tyrosine Kinases (D12.776.543.750.060); Infectious Disease Medicine (H02.403.429.480)
Guideline Contact
Chiara Speziale (guidancedocuments@escmid.org)
Publication Scope
treatment
Guideline Publication Status
Published
Languages
English
Authors
ESCMID
Publication Year
2018

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of Targeted and Biological Therapies: An Infectious Diseases Perspective (Introduction)

MeSH Terms
Biological Therapy (E02.095); Infectious Disease Medicine (H02.403.429.480)
Guideline Contact
Chiara Speziale (guidancedocuments@escmid.org)
Publication Scope
treatment
Guideline Publication Status
Published
Languages
English
Authors
ESCMID
Publication Year
2018

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of Targeted and Biological Therapies: An Infectious Diseases Perspective (Soluble Immune Effector Molecules [I]: Anti-Tumor Necrosis Factor-α Agents)

MeSH Terms
Biological Therapy (E02.095); Infectious Disease Medicine (H02.403.429.480); Tumor Necrosis Factor-alpha (D23.529.374.500.800); Tumor Necrosis Factor-alpha (D12.776.467.374.750.626); Tumor Necrosis Factor-alpha (D12.644.276.374.750.626); Tumor Necrosis Factor-alpha (D23.529.374.750.626); Tumor Necrosis Factor-alpha (D12.776.467.972.626); Tumor Necrosis Factor-alpha (D12.644.276.972.626); Tumor Necrosis Factor-alpha (D23.529.972.626)
Guideline Contact
Chiara Speziale (guidancedocuments@escmid.org)
Publication Scope
treatment
Guideline Publication Status
Published
Languages
English
Authors
ESCMID
Publication Year
2018